Clinical trials, biomarkers, microbiome, genetics, AI, basic science, and emerging IBD research.
Page 56 of 65 · 3097 articles
The study suggests that being symptom-free doesn’t guarantee the gut’s microbiome, metabolome, or epithelial functions have returned to a healthy state. Diet—especially ultraprocessed-food intake—was linked to persistent...
The work targets oxidative/nitrosative stress and mucosal repair—mechanisms important in IBD—using a novel delivery vehicle that pairs an approved anti-inflammatory drug with catalytic cerium ions. If translated, this...
If hospital-treated infections raise later IBD risk—especially in people with certain immune-related genetic variants—this supports a multi-hit model of IBD and could eventually help identify higher-risk individuals...
The study suggests upadacitinib may improve both symptoms and MRI‑documented healing of perianal fistulas in Crohn’s disease, offering a potential treatment option especially for patients who have not previously received...
Postoperative recurrence after ileal resection is common in Crohn’s disease; understanding microbial changes linked to recurrence could help explain mechanisms and guide future biomarker development.
The project could reveal a new neuro-immune circuit (IL-17A acting on enteric neurons) that promotes tissue protection during intestinal inflammation, suggesting novel non-immunosuppressive therapeutic targets for IBD.
Understanding how commensal-specific CD8+ T cells are generated and become pathogenic could reveal new mechanisms contributing to IBD, pointing to future therapeutic targets. The project aims to clarify immune–microbiota...
People with longstanding ulcerative colitis face higher colorectal cancer risk; this project focuses on a specific immune/stromal cell population (ST2+ cells responding to IL-33) that may help explain how chronic...
Bile acids shape immune signaling in the gut, and this project investigates how altered bile acid pools during ileitis could contribute to Crohn’s disease—knowledge that might point to new biomarkers or treatment...
This project studies a novel enzyme target (GCPII) that is reportedly upregulated in IBD and may change glutamate signaling and barrier function; understanding it could point to new treatment strategies for people whose...
Intestinal fibrosis and strictures remain a major cause of surgery and obstruction in Crohn’s disease, and current anti-inflammatory drugs don’t reliably prevent fibrosis. If microbial choline degradation promotes...
Children with Crohn’s disease have fewer FDA‑approved advanced treatment options than adults, so clinicians and families often must choose among off‑label therapies with limited pediatric evidence.
The study could create a human-derived lab model to better understand and treat colitis caused by cancer immunotherapy, and to evaluate IBD drugs for that purpose without compromising tumor control.
FUT enzymes affect mucosal immunity and have been associated with Crohn's disease and other IBDs; understanding their function could reveal new biological mechanisms and future therapeutic targets.
The study identifies a plant extract that reduced colitis-like injury in mice and altered gut microbes and intestinal barrier markers, which could inform future preclinical work. For people with IBD, this is early-stage...
Researchers are exploring plant-derived polysaccharides as potential therapies that might reduce inflammation and protect the intestinal barrier. For people with UC, therapies that reduce pyroptosis and restore...
This study examines a combination of ustekinumab plus low‑dose upadacitinib for patients with refractory Crohn’s disease — a group with limited options after failing anti‑TNF and single‑agent therapy. Results could...
This trial is testing an investigational anti-TL1A antibody (tulisokibart/MK-7240) as a potential new treatment for moderate to severe Crohn's disease. Results could affect future treatment options if the drug proves...
A successful Phase 3 trial could provide a new treatment option specifically studied in children with moderate‑to‑severe Crohn's disease, addressing a pediatric population often underrepresented in trials.
The trial is testing risankizumab alone and in combination with investigational ABBV antibodies for moderate-to-severe Crohn’s disease and ulcerative colitis — findings could inform future treatment choices and...
Small-bowel Crohn's disease often causes strictures and fistulas and typically needs more imaging and procedural care than colonic disease, so patients and clinicians should be aware of its distinct risks and treatment...
The study suggests measurable retinal and choroidal microvascular differences in people with IBD versus controls, which could point to systemic vascular effects of inflammation and offer noninvasive biomarker...
This study presents an engineered probiotic delivery platform that could improve survival and targeted action of live microbial therapies for IBD, potentially reducing local inflammation while affecting the gut...
This review explains how genetic, microbial, immune, and stromal factors interact to cause Crohn’s disease, which helps explain why treatments often need to target specific immune pathways or biologic mechanisms....
Intestinal fibrosis causes strictures that can lead to obstruction and often require surgery; current drugs mainly reduce inflammation and do not reliably prevent or reverse fibrosis. Advances in understanding fibrosis...
Dietary strategies such as the Crohn’s Disease Exclusion Diet (CDED) may help induce remission for some people with Crohn’s disease and could be an option alongside medical therapy or enteral nutrition. Patients...
Based on the title and source metadata, this appears to be a case report related to Crohn's disease, Upadacitinib, and JAK inhibitor. The original article is from JAAD case reports.
The study identifies a sizable group of patients in Latin America with difficult-to-treat IBD—especially Crohn’s disease—highlighting higher disease severity, younger onset, and longer diagnostic delays that can affect...
Researchers are exploring circRNAs as new molecular players in IBD inflammation; that could lead to future biomarker tests or novel treatments targeting immune pathways relevant to Crohn’s disease and ulcerative colitis.
This study suggests a traditional processing method may change a common herbal used for UC so it works better in mouse and cell models, and it proposes a specific molecular pathway (LCN2‑mediated pyroptosis) that could...
Researchers are exploring new ways to deliver regenerative factors and reshape the gut microbiome in IBD.
The study is comparing common biologics given after Crohn's surgery to prevent endoscopic recurrence—a key issue for people who have had bowel resection. Knowing which drugs perform better in real‑world practice could...
A long-term study that profiles immune cells, genes, diet, and the microbiome could help identify biomarkers that predict flares or response to therapy, which matters to people living with Crohn’s or ulcerative colitis.
A new Phase 2 trial is testing MK-8690 as a potential subcutaneous treatment for moderate–severe ulcerative colitis, with clinical remission at 12 weeks as the primary goal. Positive results could point to an additional...
Researchers identify a gut microbe (Sutterella species) that may worsen intestinal inflammation by blocking AhR-driven IL-22 and IL-17 responses—pathways that help protect the gut lining.
IBD is increasingly linked with anxiety, depression, and cognitive symptoms; this study suggests gut microbes may change tryptophan metabolism in colitis and contribute to those brain-related symptoms, which could point...
AI tools like Google NotebookLM could make systematic reviews and consensus statement processes faster and less labor-intensive for IBD-related evidence, while maintaining very low rates of major factual errors.
If validated, a blood test for cytotoxic CD4+ T cells at diagnosis could help predict who is less likely to respond to anti‑TNF drugs, potentially allowing earlier selection of alternative therapies for some children...
This review describes a novel, targeted drug-delivery approach being explored for autoimmune diseases including IBD; such technology could in future enable more specific immunomodulation with fewer systemic side effects...
This study describes a new oral immunoproteasome inhibitor (ent-F10) with preclinical activity in animal models of ulcerative colitis and rheumatoid arthritis, highlighting a potential new drug-development direction that...
This paper links specific features of the gut bacterial flagellome to TLR5-driven immune activation and reports a disease-associated shift in flagellin profiles in Crohn’s disease and ulcerative colitis, suggesting...
This study reports real-world data on mirikizumab in adults with ulcerative colitis, focusing on clinical and endoscopic remission and inflammatory markers — outcomes patients and clinicians use to judge treatment...
This NIH natural-history study is collecting clinical, immune, and genetic samples from people with Crohn’s disease and ulcerative colitis to better understand immune pathways and molecular causes of IBD. Those findings...
Mucosal healing is an important treatment goal linked to better long-term outcomes, and current anti-TNF therapies achieve mucosal healing in a minority of patients. If adding CDED improves healing, it could offer a...
Patients and families with pediatric UC may be interested because the study tests FMT plus partial enteral nutrition as a potential new treatment approach for children who haven’t responded to standard therapy and as a...
Adding structured partial enteral nutrition to advanced drug therapy could offer a non-pharmacologic way to improve short-term, steroid-free remission rates in active Crohn's disease if the trial shows benefit.
Genetic primary bile acid malabsorption can produce IBD-like symptoms and may be missed in children labeled with Crohn's disease; recognizing PBAM could change testing and management for some patients.
The paper proposes a specific molecular link between elevated glycocholic acid (a bile acid altered in IBD) and impaired intestinal stem cell renewal via the TRIB3–ID1 pathway, which could help explain poor mucosal...
